Fulgent Acquires Bako and StrataDx for $55.5 Million
- Acquisition Announcement: Fulgent Genetics has announced a definitive agreement to acquire selected assets of Bako Diagnostics and StrataDx for approximately $55.5 million, which is expected to close in the first half of 2026, marking a significant expansion in its laboratory services platform in the pathology testing market.
- Market Expansion: This acquisition will enable Fulgent to add new products and services, further expanding its national client base and sales team, which is anticipated to enhance the company's competitiveness in the rapidly growing medical testing market.
- Technology Integration: Fulgent plans to leverage its foundational technology platform alongside the expertise from Bako and StrataDx to improve service efficiency and quality, driving continued momentum in its laboratory services business, with expectations of achieving double-digit organic growth.
- Strategic Fit: CEO Ming Hsieh emphasized the strategic significance of the acquisition, stating that by integrating advanced technology and specialized expertise, Fulgent aims to enhance client experience and accelerate market penetration, thereby solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Analyst Views on FLGT
About FLGT
About the author
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Fulgent Genetics (FLGT) Options Volume Hits 1,085 Contracts, 52.7% of Average Daily Volume
- Active Options Trading: Fulgent Genetics (FLGT) has seen an options volume of 1,085 contracts today, equivalent to approximately 108,500 shares, representing 52.7% of its average daily trading volume of 205,750 shares over the past month, indicating heightened market interest in FLGT.
- High Volume Put Options: The $25 strike put option for FLGT is particularly active, with 1,068 contracts traded today, representing about 106,800 underlying shares, reflecting investor expectations of potential downward price movement.
- Morgan Stanley Options Activity: Concurrently, Morgan Stanley (MS) has recorded an options volume of 24,708 contracts today, translating to approximately 2.5 million shares, which is 51% of its average daily trading volume of 4.8 million shares over the past month, showcasing strong market interest in MS.
- High Volume Call Options: Among MS options, the $185 strike call option has seen a trading volume of 1,169 contracts, representing around 116,900 underlying shares, indicating increased investor confidence in MS's potential price appreciation.
Fulgent Acquires Bako and StrataDx for $55.5 Million
- Acquisition Announcement: Fulgent Genetics has announced a definitive agreement to acquire selected assets of Bako Diagnostics and StrataDx for approximately $55.5 million, which is expected to close in the first half of 2026, marking a significant expansion in its laboratory services platform in the pathology testing market.
- Market Expansion: This acquisition will enable Fulgent to add new products and services, further expanding its national client base and sales team, which is anticipated to enhance the company's competitiveness in the rapidly growing medical testing market.
- Technology Integration: Fulgent plans to leverage its foundational technology platform alongside the expertise from Bako and StrataDx to improve service efficiency and quality, driving continued momentum in its laboratory services business, with expectations of achieving double-digit organic growth.
- Strategic Fit: CEO Ming Hsieh emphasized the strategic significance of the acquisition, stating that by integrating advanced technology and specialized expertise, Fulgent aims to enhance client experience and accelerate market penetration, thereby solidifying its leadership position in the industry.
Transcript of Fulgent Genetics (FLGT) Earnings Call
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Fulgent Genetics increases 2025 revenue forecast to $325M fueled by new product growth
Management Insights: CEO Ming Hsieh reported sustained business momentum in Q3 2025, with growth in laboratory services driven by AI investments and an advancing therapeutic pipeline, including promising results from Phase II trials of FID-007 for head and neck cancer.
Financial Performance: Fulgent Genetics achieved $84.1 million in revenue for Q3, with improved gross margins and a reduced GAAP loss of $6.6 million, while also raising its full-year revenue outlook to $325 million and revising EPS guidance positively.
Product Innovations: The company launched an ultrarapid whole genome sequencing service and expanded its Beacon carrier screening panel, enhancing its capabilities in detecting rare genetic conditions and positioning itself competitively in the market.
Outlook and Risks: Management expressed confidence in operational efficiencies and growth prospects, despite acknowledging risks related to billing software changes and the adoption of new products, while monitoring payer reimbursement dynamics and clinical trial costs.
Today's Options Volatility and Implied Earnings Changes - November 07, 2025
Earnings Reports: Major companies such as Brookfield Infrastructure, Enbridge, and Wendy's are set to report earnings today, with expected stock movements based on options prices.
Options Activity: Investors are closely monitoring options activity prior to earnings announcements to gauge potential stock price movements.
Implied Moves: A list of companies reporting earnings includes their expected stock price changes, with notable movements for Canopy Growth (+13.76%) and Algonquin Power (+17.48%).
Trading Risks: The article emphasizes the risks associated with options trading and advises thorough research before participating.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Fulgent Genetics (FLGT) Options Volume Hits 1,085 Contracts, 52.7% of Average Daily Volume
- Active Options Trading: Fulgent Genetics (FLGT) has seen an options volume of 1,085 contracts today, equivalent to approximately 108,500 shares, representing 52.7% of its average daily trading volume of 205,750 shares over the past month, indicating heightened market interest in FLGT.
- High Volume Put Options: The $25 strike put option for FLGT is particularly active, with 1,068 contracts traded today, representing about 106,800 underlying shares, reflecting investor expectations of potential downward price movement.
- Morgan Stanley Options Activity: Concurrently, Morgan Stanley (MS) has recorded an options volume of 24,708 contracts today, translating to approximately 2.5 million shares, which is 51% of its average daily trading volume of 4.8 million shares over the past month, showcasing strong market interest in MS.
- High Volume Call Options: Among MS options, the $185 strike call option has seen a trading volume of 1,169 contracts, representing around 116,900 underlying shares, indicating increased investor confidence in MS's potential price appreciation.
Fulgent Acquires Bako and StrataDx for $55.5 Million
- Acquisition Announcement: Fulgent Genetics has announced a definitive agreement to acquire selected assets of Bako Diagnostics and StrataDx for approximately $55.5 million, which is expected to close in the first half of 2026, marking a significant expansion in its laboratory services platform in the pathology testing market.
- Market Expansion: This acquisition will enable Fulgent to add new products and services, further expanding its national client base and sales team, which is anticipated to enhance the company's competitiveness in the rapidly growing medical testing market.
- Technology Integration: Fulgent plans to leverage its foundational technology platform alongside the expertise from Bako and StrataDx to improve service efficiency and quality, driving continued momentum in its laboratory services business, with expectations of achieving double-digit organic growth.
- Strategic Fit: CEO Ming Hsieh emphasized the strategic significance of the acquisition, stating that by integrating advanced technology and specialized expertise, Fulgent aims to enhance client experience and accelerate market penetration, thereby solidifying its leadership position in the industry.
Transcript of Fulgent Genetics (FLGT) Earnings Call
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Fulgent Genetics increases 2025 revenue forecast to $325M fueled by new product growth
Management Insights: CEO Ming Hsieh reported sustained business momentum in Q3 2025, with growth in laboratory services driven by AI investments and an advancing therapeutic pipeline, including promising results from Phase II trials of FID-007 for head and neck cancer.
Financial Performance: Fulgent Genetics achieved $84.1 million in revenue for Q3, with improved gross margins and a reduced GAAP loss of $6.6 million, while also raising its full-year revenue outlook to $325 million and revising EPS guidance positively.
Product Innovations: The company launched an ultrarapid whole genome sequencing service and expanded its Beacon carrier screening panel, enhancing its capabilities in detecting rare genetic conditions and positioning itself competitively in the market.
Outlook and Risks: Management expressed confidence in operational efficiencies and growth prospects, despite acknowledging risks related to billing software changes and the adoption of new products, while monitoring payer reimbursement dynamics and clinical trial costs.
Today's Options Volatility and Implied Earnings Changes - November 07, 2025
Earnings Reports: Major companies such as Brookfield Infrastructure, Enbridge, and Wendy's are set to report earnings today, with expected stock movements based on options prices.
Options Activity: Investors are closely monitoring options activity prior to earnings announcements to gauge potential stock price movements.
Implied Moves: A list of companies reporting earnings includes their expected stock price changes, with notable movements for Canopy Growth (+13.76%) and Algonquin Power (+17.48%).
Trading Risks: The article emphasizes the risks associated with options trading and advises thorough research before participating.
